SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-16-004474
Filing Date
2016-03-30
Accepted
2016-03-30 16:14:49
Documents
3
Period of Report
2016-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20160324x8k.htm 8-K 52552
2 EX-99.1 acrs-20160324ex99145a556.htm EX-99.1 19192
3 GRAPHIC acrs20160324ex99145a556001.jpg GRAPHIC 9546
  Complete submission text file 0001558370-16-004474.txt   86346
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 161539808
SIC: 2834 Pharmaceutical Preparations